Rice Hall James & Associates LLC Has $14,903,000 Position in LivaNova PLC (LIVN)
Rice Hall James & Associates LLC reduced its position in shares of LivaNova PLC (NASDAQ:LIVN) by 1.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 296,705 shares of the company’s stock after selling 3,458 shares during the period. Rice Hall James & Associates LLC owned 0.61% of LivaNova PLC worth $14,903,000 as of its most recent filing with the SEC.
A number of other large investors also recently bought and sold shares of the stock. LS Investment Advisors LLC raised its stake in LivaNova PLC by 70.7% in the second quarter. LS Investment Advisors LLC now owns 2,840 shares of the company’s stock worth $143,000 after buying an additional 1,176 shares in the last quarter. Advisory Services Network LLC raised its stake in LivaNova PLC by 7.8% in the second quarter. Advisory Services Network LLC now owns 3,508 shares of the company’s stock worth $176,000 after buying an additional 253 shares in the last quarter. Capstone Asset Management Co. bought a new stake in LivaNova PLC during the second quarter worth about $204,000. AXA bought a new stake in LivaNova PLC during the first quarter worth about $291,000. Finally, Parametrica Management Ltd bought a new stake in LivaNova PLC during the second quarter worth about $308,000. 63.67% of the stock is currently owned by institutional investors.
Shares of LivaNova PLC (NASDAQ:LIVN) traded down 0.28% during midday trading on Tuesday, hitting $60.27. The stock had a trading volume of 272,536 shares. The stock has a 50 day moving average of $60.74 and a 200-day moving average of $54.05. The company’s market cap is $2.94 billion. LivaNova PLC has a one year low of $46.79 and a one year high of $77.00.
LIVN has been the topic of a number of analyst reports. WBB Securities reaffirmed a “hold” rating and issued a $60.00 price target on shares of LivaNova PLC in a research report on Wednesday, August 31st. Piper Jaffray Cos. reissued an “overweight” rating and set a $70.00 target price (up previously from $59.00) on shares of LivaNova PLC in a research report on Friday, August 5th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $67.20.
In other news, insider Jacques Gutedel sold 4,000 shares of the company’s stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $60.52, for a total value of $242,080.00. Following the completion of the sale, the insider now owns 10,948 shares of the company’s stock, valued at $662,572.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Two S.C.A. Equinox sold 208,000 shares of the company’s stock in a transaction dated Thursday, September 8th. The stock was sold at an average price of $60.52, for a total value of $12,588,160.00. The disclosure for this sale can be found here. Company insiders own 0.70% of the company’s stock.
LivaNova PLC Company Profile
LivaNova PLC is a medical technology company. The Company operates through three segments: Cardiac Surgery, Cardiac Rhythm Management (CRM) and Neuromodulation. The Cardiac Surgery business unit is engaged in the development, production and sale of cardiovascular surgery products, including oxygenators, heart-lung machines, perfusion tubing systems and systems for autotransfusion and autologous blood washing.
Receive News & Stock Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related stocks with our FREE daily email newsletter.